ACS Synthetic BiologySynthetic BiologyPeer-reviewed journal article
Rational Design of a Bifunctional AND-Gate Ligand to Modulate Cell-Cell Interactions
Jungmin LeeiD, Andyna VernetiD, Katherine Redfield Chan, Shulin Lu, Ionita Calin GhiraniD, Jeffrey C. WayiD, Pamela A. SilveriD
Abstract
Protein \"AND-gate\" systems, in which a ligand acts only on cells with two different receptors, direct signaling activity to a particular cell type and avoid action on other cells. In a bifunctional AND-Gate protein, the molecular geometry of the protein domains is crucial. Here we constructed a tissue-targeted erythropoietin (EPO) that stimulates red blood cell (RBC) production without triggering thrombosis. EPO was directed to RBC precursors and mature RBCs by fusion to an anti-glycophorin A antibody V region. Many such constructs activated EPO receptors in vitro and stimulated RBC and not platelet production in mice but nonetheless enhanced thrombosis in mice and caused adhesion between RBCs and EPO receptor-bearing cells. Based on a protein-structural model of the RBC surface, we rationally designed an anti-glycophorin/EPO fusion that does not induce cell adhesion in vitro or enhance thrombosis in vivo. Thus, meso-scale geometry can inform design of synthetic-biological systems.\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=138 SRC=\"FIGDIR/small/711549v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (22K):\norg.highwire.dtl.DTLVardef@93b382org.highwire.dtl.DTLVardef@ee37ccorg.highwire.dtl.DTLVardef@1913fe4org.highwire.dtl.DTLVardef@f998b1_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: protein structure
- research focus: drug response / drug discovery
- research focus: protein design
- approach: experimental assay
- Citations
- 7
- FWCI
- 0.88
- Field percentile
- top 24%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rational design of selective bispecific EPO-R/CD131 agonists
Kailyn E. Doiron, Jeffrey C. Way, Pamela A. Silver·Protein Engineering Design and SelectionPeer-reviewed·Jan 1, 2025
- Rational engineering of an erythropoietin fusion protein to treat hypoxia
Jungmin Lee, Andyna Vernet, … Pamela A. Silver·Protein Engineering Design and SelectionPeer-reviewed·Jan 1, 2021
- Designed Transmembrane Proteins Inhibit the Erythropoietin Receptor in a Custom Binding Topology
M. Mravic, L. He, … W. F. DeGrado·bioRxiv·Feb 13, 2023
- Engineering inducible signaling receptors to enable erythropoietin-free erythropoiesis
Aadit P. Shah, Kiran R. Majeti, … M. Kyle Cromer·bioRxiv·Apr 12, 2024
- Integrin-independent Tie2 activation using de novo designed proteins
Clara McCurdy, Yan Ting Zhao, … Hannele Ruohola‐Baker·bioRxiv·May 2, 2026
- Eps8 is a convergence point integrating EGFR and integrin trafficking and crosstalk
Nikki R Paul, Joanna R Thomas, … Mark R Morgan·bioRxiv·Sep 4, 2018